Oramed Pharmaceuticals Inc. — Director's Dealing 2022

May 10, 2022

SEC Form 4/A — Form 4/A

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2022-01-03

Reporting Person: Mayer Arie (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-03	Common Stock	A	6000	—	Acquired	6000	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,500 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F2: This amendment is being filed to correct an administrative error in the Form 4 filed by Dr. Mayer, which reported that 9,000 shares of common stock were beneficially owned by him following the reported transaction. Dr. Mayer beneficially owned 6,000 shares of common stock following the reported transaction.